Literature DB >> 15205351

Heritability and linkage analysis of sensitivity to cisplatin-induced cytotoxicity.

M Eileen Dolan1, Karla G Newbold, Ramamoorthy Nagasubramanian, Xiaolin Wu, Mark J Ratain, Edwin H Cook, Judith A Badner.   

Abstract

Little is known about the genetic determinants explaining variation in sensitivity to chemotherapeutic cytotoxicity. We characterized the degree of cisplatin sensitivity, using lymphoblastoid cell lines derived from 10 Centre d'Etude du Polymorphisme Humain pedigrees. We estimated the heritability for susceptibility to cisplatin-induced cytotoxicity to be approximately 0.47; therefore, sensitivity to the cytotoxic effects of cisplatin is under appreciable genetic influence. Linkage analysis was performed, and the strongest signal (lod score, 2.16; empirical P = 0.0005) was found on chromosome 1 at 44 cM. Susceptibility to cisplatin-induced cytotoxicity is likely due to multiple loci, with low locus-specific heritability contributing to the trait. These data show the power of using large pedigrees that have been extensively genotyped for evaluating the genetic contribution to sensitivity to cell growth inhibition by anticancer agents.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15205351     DOI: 10.1158/0008-5472.CAN-04-0340

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  59 in total

Review 1.  Phenotyping patient-derived cells for translational studies in cardiovascular disease.

Authors:  Stanley Y Shaw; Ari D Brettman
Journal:  Circulation       Date:  2011-11-29       Impact factor: 29.690

2.  Disease allele-dependent small-molecule sensitivities in blood cells from monogenic diabetes.

Authors:  Stanley Y Shaw; David M Blodgett; Maggie S Ma; Elizabeth C Westly; Paul A Clemons; Aravind Subramanian; Stuart L Schreiber
Journal:  Proc Natl Acad Sci U S A       Date:  2010-12-23       Impact factor: 11.205

Review 3.  The use of genomic information to optimize cancer chemotherapy.

Authors:  Federico Innocenti; Nancy J Cox; M Eileen Dolan
Journal:  Semin Oncol       Date:  2011-04       Impact factor: 4.929

Review 4.  The pharmacogenetics research network: from SNP discovery to clinical drug response.

Authors:  K M Giacomini; C M Brett; R B Altman; N L Benowitz; M E Dolan; D A Flockhart; J A Johnson; D F Hayes; T Klein; R M Krauss; D L Kroetz; H L McLeod; A T Nguyen; M J Ratain; M V Relling; V Reus; D M Roden; C A Schaefer; A R Shuldiner; T Skaar; K Tantisira; R F Tyndale; L Wang; R M Weinshilboum; S T Weiss; I Zineh
Journal:  Clin Pharmacol Ther       Date:  2007-03       Impact factor: 6.875

5.  Genomic profiling in CEPH cell lines distinguishes between the camptothecins and indenoisoquinolines.

Authors:  Venita Gresham Watson; Nicholas E Hardison; Tyndall Harris; Alison Motsinger-Reif; Howard L McLeod
Journal:  Mol Cancer Ther       Date:  2011-07-12       Impact factor: 6.261

Review 6.  Implications of genome-wide association studies in cancer therapeutics.

Authors:  Jai N Patel; Howard L McLeod; Federico Innocenti
Journal:  Br J Clin Pharmacol       Date:  2013-09       Impact factor: 4.335

7.  Genetic variants contributing to daunorubicin-induced cytotoxicity.

Authors:  R Stephanie Huang; Shiwei Duan; Emily O Kistner; Wasim K Bleibel; Shannon M Delaney; Donna L Fackenthal; Soma Das; M Eileen Dolan
Journal:  Cancer Res       Date:  2008-05-01       Impact factor: 12.701

Review 8.  Pharmacogenetics and pharmacogenomics of anticancer agents.

Authors:  R Stephanie Huang; Mark J Ratain
Journal:  CA Cancer J Clin       Date:  2009 Jan-Feb       Impact factor: 508.702

Review 9.  Relating human genetic variation to variation in drug responses.

Authors:  Ashraf G Madian; Heather E Wheeler; Richard Baker Jones; M Eileen Dolan
Journal:  Trends Genet       Date:  2012-07-26       Impact factor: 11.639

Review 10.  Pharmacogenomics of platinum-based chemotherapy in NSCLC.

Authors:  Michelle A T Hildebrandt; Jian Gu; Xifeng Wu
Journal:  Expert Opin Drug Metab Toxicol       Date:  2009-07       Impact factor: 4.481

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.